JPRN-jRCT2080223842已完成2 期
A PHASE 2, OPEN LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF TAS-115 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1. Provided written informed consent
- •2. Confirmed IPF within five years of the registration
- •3. Have more than 50% of Forced vital capacity
- •4. Satisfies any of the following
- •Have a history of treatment either with Pirfenidone or Nintedanib
- •Have a history of treatment neither with Pirfenidone nor Nintedanib
- •5. Able to take medications orally
排除标准
- •1. Airways obstruction
- •2. A serious illness or medical condition
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients with Hydroxyurea-Resistant/ Intolerant Polycythemia Vera.Polycythemia Vera (PV)MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2017-000861-58-GBF. Hoffmann-La Roche Ltd48
进行中（未招募）
1 期
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics andPharmacodynamics of Idasanutlin Monotherapy in Patients with Hydroxyurea-Resistant/ Intolerant Polycythemia Vera.Polycythemia Vera (PV)MedDRA version: 21.1Level: LLTClassification code 10036061Term: Polycythemia veraSystem Organ Class: 100000004864EUCTR2017-000861-58-ITF. HOFFMANN - LA ROCHE LTD.20
已完成
2 期
A Phase 2 study of TAS-115 in patients with CRPCPatient with castration resistant prostate cancerJPRN-jRCT2080223393Taiho Pharmaceutical Co., Ltd.50
进行中（未招募）
1 期
To Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed dose Combination (IV FDC) OfTiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid TumorsEUCTR2022-001157-23-GRF.Hoffmann-La Roche Ltd60
进行中（未招募）
1 期
To Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed dose Combination (IV FDC) OfTiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid TumorsSolid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2022-001157-23-CYF.Hoffmann-La Roche Ltd60